All In MedTech

Device Trial Radar · NCT04236609

Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

ABILITY Diabetes Global

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,050 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,050

Actual

Start

Jun 15, 2020

Primary completion

Nov 30, 2023

Study completion Nov 30, 2024

Sponsor

Lead sponsor
Concept Medical Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jan 22, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (care provider, outcomes assessor)
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare in diabetic patients eligible for percutaneous coronary intervention (PCI) with minimal exclusion criteria, the efficacy and safety of Abluminus DES+ sirolimus- eluting stents (SES) versus XIENCE Everolimus-Eluting Stents (EES). At least 40% of patients are expected to be affected by multivessel coronary artery disease and 30% with acute coronary syndrome

Conditions

  • Diabetes
  • Coronary Artery Disease
  • Acute Coronary Syndrome

Interventions

  • Abluminus DES+ Sirolimus Eluting Stent System (SES)Device

    The Sirolimus-eluting stent manufactured by Envision and distributed by Concept Medical

  • XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)Device

    The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Ischemia-driven TLRTime frame: 1 year FU
  2. Rate of Target lesion failure TLFTime frame: 1 year FU, powered for non-inferiority

Locations

90 sites in 21 countries. Site status is shown where the registry gives one.

  • The Prince Charles Hospital

    Chermside, Australia

  • St Vincent Hospital

    Melbourne, Australia

  • The Wollongong Hospital

    Wollongong, Australia

87 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.